Washington Drug Letter

Nov. 5, 2012 | Vol. 44 No. 44

Watson Dispute Resolution Request For Vaginal Gel Rejected by FDA

Watson Pharmaceuticals was dealt a blow when the FDA denied its formal dispute resolution request (FDRR) seeking approval for its progesterone vaginal gel.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Compounders Plan to Storm Capitol Hill to Save an Industry ‘Under Siege’House Committee Investigates FDA Official’s Sudden Departure FDA Rejects Endo Petition To Deny Opana Generics FDA to Focus on HIV in Next Patient-Focused Drug Development Meeting

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.